Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03486392 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 474
- Enrollment target
NCT03486392 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 474 participants.
The verdict
NCT03486392, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 474 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo after 26 weeks of treatment on the percent change in body weight from baseline and to assess the safety and tolerability, in non-diabetic severely obese participants.
Interventions
- DRUG Placebo
- DRUG Liraglutide
- DRUG JNJ-64565111 Dose Level 1
- DRUG JNJ-64565111 Dose Level 2
- DRUG JNJ-64565111 Dose Level 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 474 participants |
| Start Date | 2018-03-26 |
| Est. Completion | 2019-03-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03486392
The ClinicalTrials.gov registry entry for NCT03486392 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 474 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03486392 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03486392 about?
NCT03486392 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants". The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo after 26 weeks of treatment on the percent change in body weight from baseline and to assess the safety and tolerability, in non-diabetic severely obese participants.
What is the current status of trial NCT03486392?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 474 participants. The study started on 2018-03-26. Estimated completion is 2019-03-08.
What interventions are being tested in trial NCT03486392?
The interventions under investigation include: Placebo (DRUG), Liraglutide (DRUG), JNJ-64565111 Dose Level 1 (DRUG), JNJ-64565111 Dose Level 2 (DRUG), JNJ-64565111 Dose Level 3 (DRUG).
Who is sponsoring clinical trial NCT03486392?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.